<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;C05C&quot;,&quot;href&quot;:&quot;atc/C05C.md&quot;},{&quot;label&quot;:&quot;diosmin&quot;}]"></div>

# diosmin

- **generic name:** diosmin
- **ATC codes:** `C05CA03`
- **DrugBank:** [DB08995](https://go.drugbank.com/drugs/DB08995) · **PubChem:** [CID 5281613](https://pubchem.ncbi.nlm.nih.gov/compound/5281613)
- **molar mass:** 608.5447 g/mol (C28H32O15) — DrugBank
- **groups:** approved, investigational

## About

Diosmin is a bioflavonoid used as a capillary-stabilizing and vasoprotective medicine, mainly for vein and circulation problems such as haemorrhoids and chronic venous disease. It is approved and used in many countries, particularly in Europe, often in combination with hesperidin; it is not authorised centrally in the European Union.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q2607865](https://www.wikidata.org/wiki/Q2607865) and the WHO ATC classification; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-01 15:48 | 7:56 | 0/0/0 | 1/2/0 | 0/0/0 | 148,949/5,596 | ollama / glm-5.3-flash | 3 | 3/16 | 3/0 | 0 |

## popPK records

_not available_

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="In-vitro data (cells, tissue or microsomes), not measured in people (from the LLM relevance screen, p(non-human) 1.00).">in vitro</span> | [Artanti_2024_HepG2_cell_viability](drugs/drug_diosmin/pd_Artanti_2024_HepG2_cell_viability.md) | HepG2 cell viability ← diosmin · direct linear effect | — | Artanti AN et al., Hesperidin and Diosmin Increased Cytoto…, Asian Pacific journal of ca… (2024) | [10.31557/APJCP.2024.25.12.4247](https://doi.org/10.31557/APJCP.2024.25.12.4247) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--species" title="In-vitro data (cells, tissue or microsomes), not measured in people (from an LLM reading of the title and abstract by glm-5.3-flash, p(non-human) 0.00).">in vitro</span> | [Kuntz_1999_cell_proliferation_growth_inhibition](drugs/drug_diosmin/pd_Kuntz_1999_cell_proliferation_growth_inhibition.md) | cell proliferation (growth inhibition) ← diosmin · direct Emax (saturable) effect | — | Kuntz S et al., Comparative analysis of the effects of…, European journal of nutriti… (1999) | [10.1007/s003940050054](https://doi.org/10.1007/s003940050054) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--species" title="In-vitro data (cells, tissue or microsomes), not measured in people (from the LLM relevance screen, p(non-human) 1.00).">in vitro</span> | [Rajasekar_2025_MTT](drugs/drug_diosmin/pd_Rajasekar_2025_MTT.md) | cell proliferation (MTT assay cytotoxicity in Hep-2 cells) ← diosmin · inhibition effect | — | Rajasekar M et al., Diosmin induces mitochondrial-mediated…, Naunyn-Schmiedeberg's archi… (2025) | [10.1007/s00210-024-03690-8](https://doi.org/10.1007/s00210-024-03690-8) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=diosmin) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | blood-brain barrier | `ABCB1` inhibitor | DrugBank actor |
| absorption | kidney | `ABCB1` inhibitor | DrugBank actor |
| absorption | liver | `ABCB1` inhibitor, `SLCO2B1` unknown | DrugBank actor |
| absorption | placenta | `ABCB1` inhibitor | DrugBank actor |
| absorption | small intestine | `ABCB1` inhibitor, `SLCO2B1` unknown | DrugBank actor |
| absorption | testis | `ABCB1` inhibitor | DrugBank actor |
| distribution | blood | `ALB` binder | DrugBank actor |
| metabolism | liver | `CYP2C9` inhibitor, `CYP2E1` inhibitor, `CYP3A4` inhibitor, `SLCO1B1` inhibitor, `SLCO1B3` unknown | DrugBank actor |
| metabolism | lung | `CYP1A1` inducer | DrugBank actor |
| metabolism | small intestine | `CYP1A1` inducer, `CYP3A4` inhibitor | DrugBank actor |
| excretion | kidney | <sub>named in DrugBank's ADME text</sub> | prose |

<sub>Actors without a tissue in the table: AHR (target).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 70 matched, 59 returned
- **screened:** 10  ·  **relevant:** 0
- **records:** 0  ·  extracted 0  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** True

## Full text wanted

_14 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Ma_2007.pdf` | Ma YL et al., [Studies on pharmacokinetics of diosmin…, Zhongguo Zhong yao za zhi =… (2007) | popPK | 9 | not captured | [17511149](https://pubmed.ncbi.nlm.nih.gov/17511149) | The study is a pharmacokinetic investigation of diosmin in rats fitting a one-compartment model, but the specific numeric parameter values (CL, V, ka, etc.) are not present in the provided evidence. |
| `Russo_2015.pdf` | Russo R et al., Pharmacokinetic Profile of µSMIN Plus™,…, Natural product communicati… (2015) | popPK | 8 | not captured | [26594761](https://pubmed.ncbi.nlm.nih.gov/26594761) | The study reports quantitative PK parameters (Cmax, Tmax, AUC, t1/2) for diosmin in rats, but the specific numeric values are not present in the provided text evidence. |
| `El-Shiekh_2024.pdf` | El-Shiekh RA et al., Natural compounds as possible anti-SARS…, Natural product research (2024) | pd | 5 | [10.1080/14786419.2023.2261069](https://doi.org/10.1080/14786419.2023.2261069) | [37752734](https://www.ncbi.nlm.nih.gov/pubmed/37752734) | metadata signals extractable PD data (IC50) |
| `Cho_2020.pdf` | Cho YW et al., Small molecule inhibitors of IκB kinase…, Bioorganic & medicinal chem… (2020) | pd | 4 | [10.1016/j.bmc.2020.115440](https://doi.org/10.1016/j.bmc.2020.115440) | [32205046](https://www.ncbi.nlm.nih.gov/pubmed/32205046) | metadata signals extractable PD data (IC50) |
| `Dubey_2021.pdf` | Dubey K et al., Exploration of Diosmin to Control Diabe…, Current computer-aided drug… (2021) | pd | 4 | [10.2174/1573409916666200324135734](https://doi.org/10.2174/1573409916666200324135734) | [32208122](https://www.ncbi.nlm.nih.gov/pubmed/32208122) | metadata signals extractable PD data (IC50) |
| `Kavutcu_1999.pdf` | Kavutcu M et al., In vitro effects of selected flavonoids…, Die Pharmazie (1999) | pd | 4 | not captured | [10399192](https://www.ncbi.nlm.nih.gov/pubmed/10399192) | metadata signals extractable PD data (IC50) |
| `Kiran_2024.pdf` | Kiran KS et al., Diosmin: A Daboia russelii venom PLA2s…, Journal of ethnopharmacology (2024) | pd | 4 | [10.1016/j.jep.2023.116977](https://doi.org/10.1016/j.jep.2023.116977) | [37544341](https://www.ncbi.nlm.nih.gov/pubmed/37544341) | metadata signals extractable PD data (IC50) |
| `Kuppusamy_2017.pdf` | Kuppusamy A et al., Combining in silico and in vitro approa…, International journal of bi… (2017) | pd | 4 | [10.1016/j.ijbiomac.2016.11.062](https://doi.org/10.1016/j.ijbiomac.2016.11.062) | [27871793](https://www.ncbi.nlm.nih.gov/pubmed/27871793) | metadata signals extractable PD data (IC50) |
| `Liu_2025.pdf` | Liu Y et al., Preparation of monoclonal antibody agai…, Talanta (2025) | pd | 4 | [10.1016/j.talanta.2024.126871](https://doi.org/10.1016/j.talanta.2024.126871) | [39276572](https://www.ncbi.nlm.nih.gov/pubmed/39276572) | metadata signals extractable PD data (IC50) |
| `Vyas_2024.pdf` | Vyas K et al., Study of an inhibitory effect of plant…, International journal of bi… (2024) | pd | 4 | [10.1016/j.ijbiomac.2024.129222](https://doi.org/10.1016/j.ijbiomac.2024.129222) | [38185307](https://www.ncbi.nlm.nih.gov/pubmed/38185307) | metadata signals extractable PD data (IC50) |
| `Wang_2005.pdf` | Wang X et al., Flavonoids as a novel class of human or…, Drug metabolism and disposi… (2005) | pd | 4 | [10.1124/dmd.105.005926](https://doi.org/10.1124/dmd.105.005926) | [16081670](https://www.ncbi.nlm.nih.gov/pubmed/16081670) | metadata signals extractable PD data (IC50) |
| `Bedada_2017.pdf` | Bedada SK et al., Influence of diosmin on the metabolism…, Xenobiotica; the fate of fo… (2017) | pgx | 7 | [10.1080/00498254.2016.1244368](https://doi.org/10.1080/00498254.2016.1244368) | [27690733](https://www.ncbi.nlm.nih.gov/pubmed/27690733) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Poór_2018.pdf` | Poór M et al., Pharmacokinetic interaction of diosmeti…, Biomedicine & pharmacothera… (2018) | pgx | 7 | [10.1016/j.biopha.2018.03.146](https://doi.org/10.1016/j.biopha.2018.03.146) | [29710546](https://www.ncbi.nlm.nih.gov/pubmed/29710546) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |
| `Rajnarayana_2007.pdf` | Rajnarayana K et al., Bioavailability of diclofenac sodium af…, Drug metabolism and drug in… (2007) | pgx | 7 | [10.1515/dmdi.2007.22.2-3.165](https://doi.org/10.1515/dmdi.2007.22.2-3.165) | [17708066](https://www.ncbi.nlm.nih.gov/pubmed/17708066) | metadata signals extractable PGX data (CYP2C9, PK/PD-context) |

<sub>queue written 2026-10-01T15:47:59.046965+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Al-Mur_2024 | irrelevant | 0 | 0 | This is a phytochemical/bioactivity study of seaweed extract; diosmin appears only as an HPLC-detected flavonoid content (121.745 mg/g), with no pharmacokinetic parameters. |
| PD | Al-Mur_2024 | not_relevant | 1 | 1 | Diosmin is only quantified as a phytochemical constituent of seaweed extract; IC50 values are for crude extract cytotoxicity/antioxidant assays, not a diosmin exposure- or dose-response PD relationship. |
| popPK | Amaliah_2025 | irrelevant | 0 | 0 | The paper is a review of ternary solid dispersions where diosmin is only one of many drugs listed, and the entry for diosmin reports only antioxidant activity, not pharmacokinetic parameters. |
| PD | Amaliah_2025 | not_relevant | 0 | 0 | The paper is a review of ternary solid dispersions and does not report any specific pharmacodynamic or exposure-response data for diosmin. |
| popPK | Amato_1994 | irrelevant | 1 | 0 | Clinical efficacy trial of micronized vs nonmicronized diosmin with no PK disposition parameters reported. |
| PD | Amato_1994 | not_relevant | 2 | 0 | The paper reports clinical and plethysmographic outcomes comparing two formulations but does not provide plasma concentration data or numeric pharmacodynamic parameters (e.g., Emax, EC50) to define an exposure-response relationship. |
| popPK | Amiel_1998 | irrelevant | 1 | 0 | Pharmacodynamic (venous tone) study with no PK disposition parameters or numeric values reported. |
| PD | Amiel_1998 | not_relevant | 2 | 1 | The text describes a qualitative pharmacodynamic effect (venous tone reinforcement) and duration but provides no numeric concentration-effect data, dose-response curve, or PD parameters (Emax, EC50) for diosmin. |
| popPK | Artanti_2024 | irrelevant | 0 | 0 | In vitro cytotoxicity study (IC50, CI values) with no pharmacokinetic disposition parameters for diosmin. |
| PGx | Bedada_2017 | not_relevant | 0 | 0 | The study investigates a drug-drug interaction (diosmin affecting carbamazepine PK) and does not report any pharmacogenomic effects (gene variants) on diosmin's PK or PD parameters. |
| popPK | Chinnam_2010 | irrelevant | 0 | 0 | In-vitro enzymology study of bioflavonoids on E. coli ATP synthase; no PK parameters for diosmin. |
| PD | Chinnam_2010 | not_relevant | 4 | 3 | The paper reports a partial inhibition range (40-60%) for diosmin but does not provide a specific IC50 or a full concentration-effect curve with numeric parameters for diosmin, unlike the other compounds listed. |
| popPK | Cho_2020 | irrelevant | 0 | 0 | In vitro enzyme inhibition screening of IKKβ; diosmin is only a hit compound with IC50 comparisons, no PK parameters reported. |
| PD | Cho_2020 | not_relevant | 0 | 0 | The paper focuses on the screening of IKKβ inhibitors and molecular docking, with no mention of diosmin or any pharmacodynamic/exposure-response analysis. |
| popPK | Cornara_2022 | irrelevant | 0 | 0 | This is a phytochemical/micromorphological study of Mentha pulegium; diosmin appears only as a plant metabolite content (mg/100 g, area %), with no PK disposition parameters. |
| PD | Cornara_2022 | not_relevant | 1 | 1 | In vitro IC50 bioassays of plant extracts (not diosmin exposure-response); no PK, no concentration-effect or dose-response PD parameters for diosmin. |
| popPK | Cospite_1989 | irrelevant | 0 | 0 | Clinical efficacy trial with no PK disposition parameters for diosmin reported. |
| PD | Cospite_1989 | not_relevant | 2 | 0 | The paper reports qualitative clinical and plethysmographic improvements comparing two formulations but provides no numeric concentration-effect data, dose-response curves, or PD parameters (Emax, EC50, etc.). |
| popPK | Dubey_2021 | irrelevant | 0 | 0 | In vitro enzyme inhibition and docking study with no pharmacokinetic disposition parameters for diosmin. |
| popPK | El-Shiekh_2024 | irrelevant | 1 | 0 | In-vitro/in-silico antiviral screening with only IC50 values and qualitative predictive ADME; no PK disposition parameters for diosmin. |
| PD | El-Shiekh_2024 | not_relevant | 0 | 0 | The paper is an in-vitro and in-silico study of natural compounds against SARS-CoV-2 and does not report pharmacokinetic or pharmacodynamic modeling, exposure-response relationships, or numeric PD parameters for diosmin. |
| popPK | Fan_2025 | irrelevant | 0 | 0 | The paper is a review of flavonoids in neurological diseases and does not report any pharmacokinetic parameters for diosmin. |
| PD | Fan_2025 | not_relevant | 1 | 0 | The paper is a narrative review of flavonoids in neurological diseases and does not report specific PK/PD data, exposure-response curves, or numeric PD parameters for diosmin. |
| popPK | Habib_2022 | irrelevant | 0 | 0 | This is a pharmacodynamic neuroprotection study in rats with no PK parameters (CL, V, ka, half-life, or PK model) reported for diosmin. |
| PD | Habib_2022 | not_relevant | 3 | 2 | The study reports a qualitative dose-response trend (50, 100, 200 mg/kg) but lacks numeric PD parameters (e.g., EC50, Emax) or concentration-effect data, as it is a preclinical efficacy study without PK/PD modeling. |
| popPK | Harasstani_2010 | irrelevant | 0 | 0 | In-vitro anti-inflammatory study in RAW 264.7 cells with IC50 values, no pharmacokinetic disposition parameters for diosmin. |
| popPK | Islam_2022 | irrelevant | 0 | 0 | The paper is a review on immune system measures against coronavirus and does not contain any pharmacokinetic data or mention of diosmin. |
| PD | Islam_2022 | not_relevant | 0 | 0 | The paper is a general review on immune system rejuvenation and does not contain any pharmacodynamic or exposure-response data for diosmin. |
| popPK | Karetová_2020 | irrelevant | 0 | 0 | Czech narrative review of diosmin/hesperidin clinical efficacy with no PK parameters (no CL, V, ka, half-life, or PK model) reported. |
| PD | Karetová_2020 | not_relevant | 2 | 1 | The paper is a qualitative review discussing mechanisms of action and clinical trial outcomes (e.g., cytokine reduction) but does not report any quantitative exposure-response or dose-response models with numeric PD parameters (Emax, EC50, etc.). |
| popPK | Kataria_2019 | irrelevant | 0 | 0 | In-silico/in-vitro medicinal chemistry study of diosmin derivatives with no pharmacokinetic disposition parameters. |
| PD | Kataria_2019 | not_relevant | 2 | 2 | The paper reports single-point IC50 values for enzyme inhibition and MIC for antibacterial activity, but lacks a full concentration-effect curve, dose-response modeling, or PK/PD analysis required for extractable pharmacodynamic parameters. |
| popPK | Kavutcu_1999 | irrelevant | 0 | 0 | In vitro enzyme inhibition study; diosmin is only one of many flavonoids tested with no PK parameters reported. |
| popPK | Khodja_2025 | irrelevant | 0 | 0 | In silico docking/phytochemistry study with no PK parameters for diosmin. |
| PD | Khodja_2025 | not_relevant | 0 | 0 | The paper reports IC50 values for the whole plant extract and binding affinities for diosmin via docking, but does not provide a concentration-effect curve or numeric PD parameters (Emax, EC50, slope) specifically for diosmin. |
| popPK | Kiran_2024 | irrelevant | 0 | 0 | This is an in vitro/in vivo pharmacodynamic study of diosmin as a PLA2 inhibitor, with no PK parameters (CL, V, ka, half-life, or population-PK model) reported. |
| popPK | Kuntz_1999 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of flavonoid effects on cancer cell proliferation and apoptosis, not a pharmacokinetic study. |
| popPK | Kuppusamy_2017 | irrelevant | 0 | 0 | In silico docking and in vitro AChE inhibition study with no pharmacokinetic disposition parameters for diosmin. |
| PD | Kuppusamy_2017 | not_relevant | 0 | 0 | The paper focuses on in silico and in vitro acetylcholinesterase inhibition of flavonoids for Alzheimer's disease and does not report pharmacokinetic or pharmacodynamic exposure-response relationships for diosmin. |
| popPK | Liu_2025 | irrelevant | 0 | 0 | This is an immunoassay method-development paper (ELISA for flavonoid detection) with no pharmacokinetic parameters for diosmin. |
| PD | Liu_2025 | not_relevant | 0 | 0 | The paper describes the preparation of a monoclonal antibody and the development of an ELISA method for quantifying rhoifolin and diosmin, containing no pharmacodynamic or exposure-response data. |
| popPK | Ma_2007 | relevant | 9 | 0 | The study is a pharmacokinetic investigation of diosmin in rats fitting a one-compartment model, but the specific numeric parameter values (CL, V, ka, etc.) are not present in the provided evidence. |
| popPK | Mahran_2019 | irrelevant | 0 | 0 | This is a natural-product isolation/phytochemistry paper; diosmin is merely an isolated compound with no pharmacokinetic parameters reported. |
| PD | Mahran_2019 | not_relevant | 0 | 0 | The paper is a phytochemical isolation study; diosmin is merely identified as one of the isolated compounds, and no pharmacodynamic or exposure-response analysis is performed for it. |
| popPK | Majnooni_2020 | irrelevant | 0 | 0 | The paper is a review of phytochemicals for lung injury and mentions diosmin only in the context of a clinical trial registration, providing no pharmacokinetic parameters. |
| PD | Majnooni_2020 | not_relevant | 0 | 0 | The paper is a narrative review of phytochemical mechanisms and does not report any specific pharmacokinetic or pharmacodynamic data, exposure-response relationships, or numeric PD parameters for diosmin. |
| popPK | Melzig_1999 | irrelevant | 0 | 0 | In-vitro pharmacodynamic study of diosmin on endothelial cells with no PK parameters. |
| popPK | Miara_2025 | irrelevant | 0 | 0 | This is a phytochemical/biological activity study of Thymbra nabateorum extract; diosmin appears only as a quantified plant constituent (118.75 mg/g), with no PK parameters for diosmin. |
| PD | Miara_2025 | not_relevant | 1 | 1 | In vitro phytochemistry/bioassay study (IC50 enzyme inhibition, cytotoxicity) of plant extracts; no in vivo exposure- or dose-response PD relationship for diosmin. |
| PGx | Michalczyk_2025 | not_relevant | 0 | 0 | The paper investigates the pharmacological interaction between diosmetin and doxorubicin in cancer cells, not the effect of genetic variants on the PK/PD of diosmin. |
| popPK | Nugroho_2013 | irrelevant | 0 | 0 | This is an HPLC quantification and antioxidant assay of plant constituents, not a pharmacokinetic study; diosmin is only a quantified analyte with no disposition parameters. |
| PD | Nugroho_2013 | not_relevant | 3 | 2 | The paper reports IC50 values for various compounds including diosmin in a peroxynitrite-scavenging assay, but this is a simple in vitro bioassay potency metric, not a pharmacodynamic (exposure-response) model or dose-response curve analysis with derivable PD parameters like Emax or slope in a PK/PD context. |
| popPK | Nureye_2025 | irrelevant | 0 | 0 | The paper is a review of medicinal plants for hypertension and does not report pharmacokinetic parameters for diosmin. |
| PD | Nureye_2025 | not_relevant | 0 | 0 | The paper is a review of medicinal plants for hypertension in Ethiopia and does not report any specific pharmacodynamic or exposure-response analysis for diosmin. |
| PGx | Orzetti_2023 | not_relevant | 2 | 3 | Reports drug–natural product interactions via CYP3A4, not a gene variant/genotype effect on diosmin PK/PD parameters. |
| popPK | Ouari_2026 | irrelevant | 0 | 0 | Evidence is only an LC-MS instrument report for a plant leaf extract with no diosmin PK parameters. |
| PD | Ouari_2026 | not_relevant | 0 | 0 | The text is raw LC-MS/MS instrument data for a plant extract sample and contains no pharmacodynamic, exposure-response, or dose-response analysis. |
| popPK | Paul_2026 | irrelevant | 0 | 0 | This is a phytochemical/antimicrobial/docking study of Achillea millefolium extract; diosmin appears only as an identified compound and docking ligand, with no PK parameters. |
| PD | Paul_2026 | not_relevant | 1 | 1 | In vitro phytochemical screening (DPPH IC50, ZOI, docking) of plant extracts; no in vivo diosmin exposure- or dose-response PD relationship or PK/PD parameters. |
| PGx | Poór_2018 | not_relevant | 0 | 0 | The paper investigates drug-drug interactions (CYP2C9 inhibition and albumin displacement) of diosmetin, not the effect of a gene variant on diosmin's PK/PD. |
| popPK | Rajasekar_2025 | irrelevant | 0 | 0 | In vitro anticancer mechanism study with no PK parameters for diosmin. |
| PGx | Rajnarayana_2007 | not_relevant | 0 | 0 | The study investigates a drug-drug interaction (diosmin affecting diclofenac PK) and does not report any pharmacogenomic effects (gene variants) on diosmin or diclofenac. |
| popPK | Rajnarayana_2008 | irrelevant | 1 | 0 | The study investigates diosmin as a CYP2E1 inhibitor affecting the pharmacokinetics of chlorzoxazone, not the disposition parameters of diosmin itself. |
| popPK | Russo_2015 | relevant | 8 | 2 | The study reports quantitative PK parameters (Cmax, Tmax, AUC, t1/2) for diosmin in rats, but the specific numeric values are not present in the provided text evidence. |
| popPK | Sher_1992 | irrelevant | 0 | 0 | In-vitro mechanistic study of amine uptake inhibition in cell lines; no PK disposition parameters for diosmin. |
| popPK | Sheridan_2022 | irrelevant | 2 | 1 | The paper is a review of polyphenol antiviral mechanisms and pharmacokinetics, mentioning diosmin only as a precursor to diosmetin without reporting original quantitative PK parameters (CL, V, Q) for diosmin itself. |
| PD | Sheridan_2022 | not_relevant | 2 | 1 | The paper is a review discussing mechanisms and citing in vitro IC50s for various polyphenols, but it does not report a specific pharmacodynamic or exposure-response model with numeric parameters for diosmin. |
| popPK | Singh_2021 | irrelevant | 0 | 0 | Diosmin is only listed as a phytochemical constituent of a plant extract; no PK parameters are reported. |
| PD | Singh_2021 | not_relevant | 0 | 0 | The paper reports an IC50 for a crude plant extract, not for the specific drug diosmin, and does not provide a dose-response curve or PD parameters for diosmin itself. |
| popPK | Sovrlić_2022 | irrelevant | 0 | 0 | In-vitro spectroscopic protein-binding study of tigecycline on HSA; diosmin is only a co-ligand, with no PK disposition parameters. |
| PD | Sovrlić_2022 | not_relevant | 0 | 0 | The study investigates in vitro binding affinity and competition for Human Serum Albumin (HSA) using spectroscopy and docking, not in vivo pharmacodynamics or exposure-response relationships. |
| popPK | Stanoiu_2025 | irrelevant | 0 | 0 | The paper focuses on the characterization of Inonotus obliquus delivery systems and does not involve diosmin or pharmacokinetic studies. |
| PD | Stanoiu_2025 | not_relevant | 0 | 0 | The paper focuses on the characterization of Inonotus obliquus delivery systems and does not mention diosmin or report any pharmacodynamic or exposure-response data. |
| popPK | Sun_2022 | irrelevant | 0 | 0 | This is an in-vitro antioxidant/LDL oxidation study of plant flavonoids; diosmin is only a minor identified component (2.88%), with no PK parameters. |
| PD | Sun_2022 | not_relevant | 0 | 0 | The paper reports in vitro antioxidant and anti-glycation activities of a flavonoid mixture (PEF) and identifies diosmin as a constituent, but it does not perform a pharmacokinetic or pharmacodynamic analysis for diosmin specifically, nor does it provide exposure-response or dose-response parameters (e.g., EC50, Emax) for diosmin in a biological system. |
| popPK | Taleghani_2025 | irrelevant | 0 | 0 | Phytochemical screening only; diosmin merely identified as a constituent, no PK parameters. |
| PD | Taleghani_2025 | not_relevant | 0 | 0 | The paper is a phytochemical and in vitro biological activity study of plant fractions; it identifies diosmin as a constituent but does not report any pharmacodynamic or exposure-response analysis for diosmin specifically. |
| popPK | Vyas_2024 | irrelevant | 0 | 0 | In vitro/in silico enzyme inhibition study with no pharmacokinetic disposition parameters for diosmin. |
| PD | Vyas_2024 | not_relevant | 0 | 0 | The paper focuses on in vitro enzyme inhibition and molecular docking of plant polyphenols, not on the pharmacokinetic or pharmacodynamic modeling of diosmin in a biological system. |
| popPK | Wahyuningsih_2026 | irrelevant | 0 | 0 | The paper is a review on nanocarrier delivery for diabetic wound healing and does not report pharmacokinetic parameters for diosmin. |
| PD | Wahyuningsih_2026 | not_relevant | 0 | 0 | The paper is a review of nanocarrier delivery systems for phytochemicals in diabetic wound healing and does not report any specific pharmacodynamic or exposure-response data for diosmin. |
| popPK | Wang_2005 | irrelevant | 1 | 1 | In-vitro transporter inhibition study (OATP1B1 in HeLa cells); diosmin is only a tested modulator, no PK disposition parameters. |
| PD | Wang_2005 | not_relevant | 0 | 0 | The paper reports in vitro transporter inhibition (IC50/Ki) for flavonoids, not a pharmacodynamic exposure-response or dose-response relationship for diosmin in a physiological or clinical context. |
| popPK | Wang_2026 | irrelevant | 0 | 0 | The paper describes a molecular foundational model for chemical structure representation and generation, containing no pharmacokinetic data or parameters for diosmin. |
| PD | Wang_2026 | not_relevant | 0 | 0 | The paper describes a molecular foundational model for chemical representation and generation, containing no pharmacodynamic or exposure-response data for diosmin. |
| popPK | Xie_2009 | irrelevant | 0 | 0 | This is a natural product isolation and cytotoxicity study; diosmin is only an isolated compound with IC50 data, no PK parameters. |
| PD | Xie_2009 | not_relevant | 0 | 0 | The paper reports an IC50 for diosmin only qualitatively as "little cytotoxic activity" without providing a specific numeric value or dose-response curve parameters. |
| popPK | Xu_2024 | irrelevant | 0 | 0 | The paper is a critical review of flavonoid drugs and does not report original quantitative pharmacokinetic parameters for diosmin. |
| PD | Xu_2024 | not_relevant | 1 | 0 | The paper is a critical review of flavonoid drug development and informatics analysis, containing no specific pharmacodynamic modeling, exposure-response data, or numeric PD parameters for diosmin. |
| popPK | Xu_2025 | irrelevant | 0 | 0 | The paper is a review of flavonoids in digestive diseases and does not report pharmacokinetic parameters for diosmin. |
| PD | Xu_2025 | not_relevant | 1 | 0 | The paper is a narrative review of flavonoids in digestive diseases and does not report specific pharmacokinetic or pharmacodynamic data, exposure-response relationships, or numeric PD parameters for diosmin. |
| popPK | Zhang_2026 | irrelevant | 0 | 0 | The paper focuses on antibacterial drug repurposing and does not study diosmin or report any pharmacokinetic parameters for it. |
| PD | Zhang_2026 | not_relevant | 0 | 0 | The paper focuses on drug repurposing for antibacterial discovery and does not mention diosmin or report any pharmacodynamic parameters for it. |

---
<sub>Generated by `docs.py` (scholarv2)</sub>
